ASCENT and DESTINY-Breast09 Trials: Applying Frontline Data in Metastatic Breast Cancer Care
Dr. Sara Tolaney joins Dr. Monty Pal to discuss optimizing the sequencing and combination of antibody-drug conjugates for metastatic HER2-positive and triple-negative breast cancer, as well as guidelines for managing serious toxicities like ILD and neutropenia.
LINK TO FULL TRANSCRIPT
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.